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URini and colleagues [1] recently reported the re-
ults of a multi-institutional study by the Cancer and
eukemia Group B (CALGB) investigating nonmy-
loablative hematopoietic cell transplantation in pa-
ients with advanced renal cell carcinoma (RCC).
wenty-two patients received conditioning with cy-
lophosphamide and ﬂudarabine followed by a gran-
locyte colony-stimulating factor mobilized periph-
ral blood stem cell transplant from an HLA-matched
ibling. Patients were eligible to receive donor lym-
hocyte infusions and/or interferon- to treat disease
rogression. Sustained engraftment was observed in
1 patients, with 17 patients achieving90% donor T
ell chimerism by day 120. Progression-free survival
3 months) and overall survival (5.5 months) were
xtremely short. Despite the presence of grade II-IV
cute and chronic graft-versus-host disease (GVHD;
2% and 23% of patients, respectively), no objective
isease responses were observed. This report brings to
ind prior early experiences of allogeneic transplan-
ation for hematologic diseases and highlights the
eed for further research of allogeneic transplantation
or metastatic RCC.
Several decades ago, when the use of allogeneic
ransplantation for chronic myelogenous leukemia
CML) was ﬁrst reported by Thomas et al [2], the
esults were exciting and disappointing; exciting in the
ense that a proportion of patients was cured, but
isappointing in terms of poor overall efﬁcacy and
ubstantial toxicity. As time went on, it became clear
hat the limited efﬁcacy of the approach was largely
elated to selecting patients with advanced CML (blast erisis) and that a substantial proportion of the mor-
idity and mortality of the procedure occurred as a
onsequence of ineffective supportive care. By the end of
he 20th century, with better patient selection criteria
nd the advent of more effective supportive care mea-
ures, approximately 80% of patients with chronic phase
ML could be expected to be cured after allogeneic
ematopoietic cell transplantation [2]. Although the suit-
bility of solid tumors as targets for allogeneic immuno-
herapy remains under investigation, this report from the
ALGB makes us ask whether history may be repeating
tself, this time for metastatic RCC.
Several analogies can be drawn from the experi-
nce of Thomas et al. First, a graft-versus-tumor
GVT) effect can be evoked against RCC; proof of
oncept was established in 2000 and 9 small case
eries since that time have reported delayed tumor
egression after transplantation consistent with a
VT effect, with long-term and occasionally com-
lete responses being observed in some patients with
idely metastatic disease (Table 1) [3]. Although cur-
ent transplantation strategies enrolling patients with
dvanced tumors and short anticipated survival may
onsiderably limit the efﬁcacy of this approach, proof
f concept and the observation of durable complete
esponses provide a foundation on which to further
evelop more effective transplantation approaches.
econd, it has been clear from the ﬁrst report of a
elayed GVT effect against RCC that a number of
actors can limit a successful transplantation outcome.
nfortunately, patients are often referred for consid-
ration of an allogeneic transplant too late in the
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N. T. Ueno and R. W. Childs32ourse of their disease, as a “last ditch effort,” when all
ther therapeutic options have failed. RCC is intrin-
ically resistant to chemotherapeutic agents, even after
hey have been dose intensiﬁed. Because the condi-
ioning regimen offers no direct tumor cytoreductive
ffect and because GVT effects against RCC appear
elayed compared with hematologic malignancies, pa-
ients often succumb to tumor progression before a
onor immune-mediated GVT effect can occur. This
elay makes careful selection of patients for the pro-
edure obligatory. Exclusion of patients with survival
o short that a GVT effect is unlikely to occur, in-
luding those with rapid tumor growth, unfavorable
istologies, hypercalcemia, and other factors predic-
ive of short survival, is necessary given this limitation.
rom the initial report of GVT effects in RCC, delays
n responses and responses being restricted to tumors of
lear cell histology were reported [3]. The extremely
hort survival in the patient cohort reported in this study
nd the failure to restrict enrollment to those with clear
ell histology suggest that investigators in this trial may
ot have adapted sufﬁciently stringent inclusion criteria
ppropriate for this type of procedure. Although earlier
eports had clearly identiﬁed this limitation, this trial was
nitiated before some of those reports were published. As
uch, this study provides additional evidence highlight-
ng the critical importance of being selective in choosing
atients with metastatic RCC who undergo transplanta-
ion. Collectively, these factors likely played a role in the
ack of a response and the short overall survival observed
n the patients presented in the CALGB study.
Although transplantation may not be advisable for
hose with rapidly advancing disease or poor prognos-
ic factors (eg, high lactate dehydrogenase levels, poor
erformance status, high calcium or hemoglobin con-
entrations), results for other patients can be quite
ood, including partial and complete responses asso-
able 1. Nonmyeloablative Allogeneic Stem Cell Transplantation for M
Study Patients, n Conditioning Agents G
hilds et al [5] 19 Flu  Cy CSA
ini et al/Artz et al 18 Flu  Cy Tac
regni et al 7 Flu  TT CSA
edrazzoli et al 7 Flu  Cy CSA
laise et al 25 Flu  Bu  ATG CSA
akagawa et al 9 Flu/Cla  Bu  ATG CSA
eno et al [4] 15 Flu  Mel Tac
entschke et al 10 Flu  TBI  ATG CSA
assenkeil et al 7 Flu  Cy  ATG CSA
ykodi et al 8 Flu  TBI CSA
arkholt et al 124 V CSA
ini et al 22 Flu  Cy Tac
GVHD indicates acute graft-versus-host disease; cGVHD, chronic
response; CR, complete response; Flu, ﬂudarabine; Cy, cycloph
mofetil; TT, thiotepa; MTX, methotrexate; Bu, busulfan; *mixeiated with a prolongation in survival compared with tonresponders [4-7]. As such, adopting necessary se-
ection criteria should not be considered “extreme”
ut rather “appropriate” given the limitations of cur-
ent nonmyeloablative transplantation approaches.
tudies of transplantation for hematologic malignan-
ies in the late 1970s and early 1980s likewise adapted
ppropriate methods to select patients who were most
ikely to beneﬁt from the procedure, with a net im-
rovement in outcome compared with early trans-
lantation results. Another important consideration is
he learning curve that comes with performing allo-
eneic transplantation on patients with solid tumors.
s pointed out by the investigators in the CALGB
rial, transplantation for solid tumors is unique from
ematologic malignancies because it requires coordi-
ation between the solid tumor “specialist” who may
ot otherwise have transplantation expertise and the
ransplantation physician who may not routinely care
or patients with RCC. Centers performing such
ransplantations need to have not only expertise in
erforming and managing complications associated
ith allogeneic transplantation but also a comprehen-
ive team approach in which medical, radiation, and
urgical oncologists are available to assist in the selec-
ion of appropriate transplant candidates and to man-
ge complications associated with tumor progression.
urther, because GVT effects can be closely linked to
VHD, using a transplantation strategy that seeks to
nduce rather than avoid alloreactivity through ag-
ressive immunosuppression withdrawal, donor lym-
hocyte infusions, and post-transplantation interferon
se, all of which increase the risk of acute and chronic
VHD, is a reasonable goal. In the CALGB trial,
nly 2 of 22 patients went on to receive donor lym-
hocyte infusions or interferon- therapy, despite
rogression occurring in most. Thus, it is important
hat physicians who investigate allogeneic transplan-
c Renal Cell Carcinoma: Series Published up to 2006
rophylaxis aGVHD (II-IV) cGVHD TRM
Response
(PR or CR)
53% 21% 11% 53%
MF 22% 39% 14% 22%
X 86% 71% 0% 57%
X 0% N/A 29% 0%
42% 60% 9% 8%
44% 44% 0% 11%
TX 47% 27% 33% 20%
F 50% 30% 40% 0%*
F 29% 57% 14% 29%
F 50% 50% 13% 13%
F or MTX 40% 33% 16% 32%
TX 32% 23% 9% 0%
versus-host disease; TRM, transplant-related mortality; PR, partial
ide; CSA, cyclosporine; Tacro, tacrolimus; MMF, mycophenolate
onse observed.etastati
VHD P
ro  M
 MT
 MT
ro  M
 MM
 MM
 MM
 MM
ro  M
graft-
osphamation for solid tumors be well versed in the nuances of
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Need for Advances in Allogeneic Hematopoietic Stem Cell Transplantation for RCC 33he disease and use appropriate and aggressive treat-
ents to manage disease progression occurring in the
arly post-transplantation window before a GVT ef-
ect has occurred. As an example, for mild skin
VHD, the use of topical rather than more globally
mmunosuppressive systemic steroids may be pre-
erred. Further, incorporating a strategy of “permis-
ive GVHD” in which immunosuppression tapering
ccurs in the setting of mild non-life-threatening
cute and chronic GVHD may also be used to opti-
ize a GVT effect against the tumor (a strategy not
ypically used for hematologic malignancies). A
reater understanding of the importance and effec-
iveness of these types of unconventional maneuvers
eems necessary before such strategies can be incor-
orated globally into transplantation protocols used in
he cooperative group setting.
So what should be done at this juncture? First, the
election of patients for allogeneic transplantation
hould be subject to strict transplantation-based
rather than disease-based) criteria. These criteria
hould be further expanded to include known prog-
ostic markers related to survival in patients with
etastatic RCC. Rather than viewing selectivity as a
ias unfairly affecting the validity of a study, we should
ake advantage of it to ﬁnd new prognostic factors that
an be used to identify those patients who would derive
he most beneﬁt from GVT effects. The recently initi-
ted multi-institutional National Marrow Donor Pro-
ram study of unrelated-donor transplantation for met-
static RCC incorporates eligibility criteria to select
hose patients most likely to beneﬁt from this approach
ncluding clear cell only histology and other variables
ssociated with survival times sufﬁcient for the induction
f a GVT effect (ie, normal calcium, lactate dehydroge-
ase, and hemoglobin levels).
Second, the fact that GVT effects against RCC ap-
ear delayed compared with hematologic malignancies
annot be ignored. Novel, innovative trials that incorpo-
ate strategies to control disease until a GVT effect can
ccur; such as through the use of tumor angiogenesis
nhibition in the immediate post-transplantation period,
ould potentially overcome this limitation.
Third, efforts should be focused on the develop-
ent of transplantation approaches that capitalize on
he induction of beneﬁcial GVT effects and avoid
VHD. The identiﬁcation of antigens targeted by the
onor immune system that are restricted to the tumor
ould lead to more effective strategies incorporating
ost-transplantation tumor vaccination or the adop-
ive infusion of in vitro expanded donor T cells reac-
ive against patient RCC cells. The adoptive infusion
f alloreactive donor natural killer cells with enhanced
ytotoxicity compared with autologous natural killer
ells is another promising area of research [8].
Fourth, recent advances in therapies targeting ty-
osine kinases involved in tumor angiogenesis (eg,unitinib malate [Sutent], sorafenib [Nexavar]) have
ecently expanded the therapeutic options for patients
ith metastatic RCC. Although these drugs do not
ppear to have the potential to cure, they can induce
artial responses and disease stabilization, signiﬁcantly
rolonging the time to tumor progression. There ex-
sts a theoretical concern that enrolling patients into
ransplantation trials for whom these agents have
ailed may further shorten the already brief window of
ime that these patients have for a GVT effect to be
nduced. Strategies that incorporate these drugs into
he transplantation regimen itself will likely be inves-
igated in the near future.
The apparent lack of effect observed in the
ALGB trial may unfortunately spur negative percep-
ions regarding the potential usefulness of transplan-
ation for metastatic RCC, particularly among those
ithout knowledge of the track record of the success-
ul evolution in efﬁcacy of allogeneic transplantation
or other malignant disorders. Although hematologic
alignancies may in general be more sensitive to
VT effects, observation of durable complete remis-
ions after allogeneic transplantation for RCC by
ther groups combined with the failure of this trial to
nduce GVT effects underscores the need for a con-
inuing commitment to research in this ﬁeld.
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